AMENDMENT NO. 1 TO PRODUCT MANUFACTURE AND SUPPLY AND FACILITY CONSTRUCTION AGREEMENTProduct Manufacture and Supply and Facility Construction Agreement • August 9th, 2018 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 to the Product Manufacture and Supply and Facility Construction Agreement (“Amendment No. 1”) is made and entered into as of April 20, 2018 (the “Amendment No. 1 Effective Date”) by and between BioVectra Inc., with its registered offices at 11 Aviation Avenue, Charlottetown, PEI, C1E 0A1, Canada (“BioVectra”) and Keryx Biopharmaceuticals, Inc., with its offices at One Marina Park Drive, 12th floor, Boston, Massachusetts, 02210, USA (“Keryx”).
PRODUCT MANUFACTURE AND SUPPLY AND FACILITY CONSTRUCTION AGREEMENTProduct Manufacture and Supply and Facility Construction Agreement • February 21st, 2018 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations
This product manufacture and supply and facility construction agreement (“Agreement”) is made and entered into on the date of last signature by and between BioVectra Inc., with its registered offices at 11 Aviation Avenue, Charlottetown, PEI, C1E 0A1, Canada (“BioVectra”) and Keryx Biopharmaceuticals, Inc., with its offices at One Marina Park Drive, 12th floor, Boston, Massachusetts, USA, 02210 (“Keryx”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AMENDED AND RESTATED PRODUCT...Product Manufacture and Supply and Facility Construction Agreement • September 11th, 2020 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This amended and restated Product Manufacture and Supply and Facility Construction Agreement (this “Amended Agreement”) is made and entered into on September 4, 2020 (“Amendment Effective Date”) by and between BioVectra Inc., with its registered offices at 11 Aviation Avenue, Charlottetown, PEI, C1E 0A1, Canada (“BioVectra”) and Keryx Biopharmaceuticals, Inc., a wholly owned subsidiary of Akebia Therapeutics, Inc., with its offices at 245 First Street, Cambridge, Massachusetts 02142, USA (“Keryx”) (each hereafter a “Party,” and together, “Parties”).
